Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Vaccine
    April 2018
  1. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged >/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30376.
    >> Share

  2. IBARZ-PAVON AB, French N
    No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi.
    Vaccine. 2018 Apr 7. pii: S0264-410X(18)30478.
    >> Share

  3. LAPUENTE D, Ruzsics Z, Thirion C, Tenbusch M, et al
    Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30262.
    >> Share

  4. SPICKNALL IH, Looker KJ, Gottlieb SL, Chesson HW, et al
    Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Vaccine. 2018 Apr 3. pii: S0264-410X(18)30254.
    >> Share

    March 2018
  5. WORLD HEALTH ORGANIZATION
    BCG vaccine: WHO position paper, February 2018 - Recommendations.
    Vaccine. 2018 Mar 30. pii: S0264-410X(18)30345.
    >> Share

  6. HARRER T, Dinges W, Roman F
    Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials.
    Vaccine. 2018 Mar 29. pii: S0264-410X(18)30388.
    >> Share

  7. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged>/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30375.
    >> Share

  8. PANDEY RK, Ojha R, Aathmanathan VS, Krishnan M, et al
    Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection.
    Vaccine. 2018 Mar 20. pii: S0264-410X(18)30387.
    >> Share

    February 2018
  9. THIAM-DIOUF A, Metch B, Sharpe C, Mulugeta R, et al
    Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
    Vaccine. 2018;36:1235-1242.
    >> Share

  10. KOURKOUNTI S, Retsas T, Paparizos V, Tsimpidakis A, et al
    Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30192.
    >> Share

  11. NELSON NP, Yankey D, Singleton JA, Elam-Evans LD, et al
    Hepatitis A vaccination coverage among adolescents (13-17years) in the United States, 2008-2016.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30163.
    >> Share

  12. SHRIVASTAVA T, Samal S, Tyagi AK, Goswami S, et al
    Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Vaccine. 2018 Feb 8. pii: S0264-410X(18)30154.
    >> Share

    January 2018
  13. DE BOER PT, Kelso JK, Halder N, Nguyen TP, et al
    The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    Vaccine. 2018 Jan 17. pii: S0264-410X(17)31836.
    >> Share

    December 2017
  14. SERWANGA J, Ssemwanga D, Muganga M, Nakiboneka R, et al
    HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
    Vaccine. 2017 Dec 20. pii: S0264-410X(17)31718.
    >> Share

  15. SHIVE CL, Judge CJ, Clagett B, Kalayjian RC, et al
    Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
    Vaccine. 2017 Dec 15. pii: S0264-410X(17)31761.
    >> Share

  16. HIBBS BF, Miller E, Shi J, Smith K, et al
    Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.
    Vaccine. 2017 Dec 13. pii: S0264-410X(17)31726.
    >> Share

  17. HABER P, Moro PL, Ng C, Lewis PW, et al
    Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31722.
    >> Share

  18. HERBECK JT, Peebles K, Edlefsen PT, Rolland M, et al
    HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31731.
    >> Share

  19. GOTTLIEB SL, Giersing BK, Hickling J, Jones R, et al
    Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492.
    >> Share

    November 2017
  20. WENIGER BG, Anglin IE, Tong T, Pensiero M, et al
    Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31479.
    >> Share

  21. NANNI A, Meredith S, Gati S, Holm K, et al
    Strengthening global vaccine access for adolescents and adults.
    Vaccine. 2017 Nov 6. pii: S0264-410X(17)31419.
    >> Share

    October 2017
  22. FROTA ACC, Ferreira B, Harrison LH, Pereira GS, et al
    Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
    Vaccine. 2017 Oct 31. pii: S0264-410X(17)31451.
    >> Share

  23. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    >> Share

  24. SLEZAK J, Meyer K, Sy LS, Chao C, et al
    An imputation method for calculating and comparing autoimmune disease incidence using partial case review.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31418.
    >> Share

  25. IZURIETA HS, Moro PL, Chen RT
    Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?
    Vaccine. 2017 Oct 12. pii: S0264-410X(17)31365.
    >> Share

  26. WU J, Zhao C, Liu Q, Huang W, et al
    Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system.
    Vaccine. 2017 Oct 11. pii: S0264-410X(17)31371.
    >> Share

  27. ANA-SOSA-BATIZ F, Johnston APR, Hogarth PM, Wines BD, et al
    Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults.
    Vaccine. 2017 Oct 10. pii: S0264-410X(17)31315.
    >> Share

  28. SUN P, Crum-Cianflone NF, Defang G, Williams M, et al
    Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.
    Vaccine. 2017 Oct 4. pii: S0264-410X(17)31307.
    >> Share

    September 2017
  29. NONZEE NJ, Baldwin SB, Cui Y, Singhal R, et al
    Disparities in parental human papillomavirus (HPV) vaccine awareness and uptake among adolescents.
    Vaccine. 2017 Sep 26. pii: S0264-410X(17)31134.
    >> Share

  30. CHENG L, Zhang Z, Li G, Li F, et al
    Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31300.
    >> Share

  31. SCHIFFER JT, Gottlieb SL
    Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273.
    >> Share

  32. TAN S, Zhang S, Wu B, Zhao Y, et al
    Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans.
    Vaccine. 2017 Sep 13. pii: S0264-410X(17)31159.
    >> Share

  33. SUNDARAMURTHI JC, Ashokkumar M, Swaminathan S, Hanna LE, et al
    HLA based selection of epitopes offers a potential window of opportunity for vaccine design against HIV.
    Vaccine. 2017 Sep 6. pii: S0264-410X(17)31168.
    >> Share

    August 2017
  34. DESHMUKH AA, Cantor SB, Fenwick E, Chiao EY, et al
    Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.
    Vaccine. 2017 Aug 11. pii: S0264-410X(17)31073.
    >> Share

  35. LI Q, Liu Q, Huang W, Wu J, et al
    An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.
    Vaccine. 2017 Aug 7. pii: S0264-410X(17)31037.
    >> Share

    July 2017
  36. WORLD HEALTH ORGANIZATION
    Measles vaccines: WHO position paper, April 2017 - Recommendations.
    Vaccine. 2017 Jul 28. pii: S0264-410X(17)30974.
    >> Share

  37. PATEL DP, Treat JR, Castelo-Socio L
    Decreased Hepatitis B vaccine response in pediatric patients with atopic dermatitis, psoriasis, and morphea.
    Vaccine. 2017 Jul 20. pii: S0264-410X(17)30933.
    >> Share

  38. JALLOW S, Madhi SA, Madimabe R, Sipambo N, et al
    Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Vaccine. 2017 Jul 5. pii: S0264-410X(17)30878.
    >> Share

    June 2017
  39. LARA AN, Sartori AM, Fonseca MO, Lopes MH, et al
    Long-term protection after hepatitis B vaccination in people living with HIV.
    Vaccine. 2017 Jun 29. pii: S0264-410X(17)30827.
    >> Share

  40. VENEREO-SANCHEZ A, Simoneau M, Lanthier S, Chahal P, et al
    Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line.
    Vaccine. 2017 Jun 22. pii: S0264-410X(17)30801.
    >> Share

  41. SILVA GP, Santos RS, Pereira-Manfro WF, Ferreira B, et al
    A cross-reacting material CRM197 conjugate vaccine induces diphtheria toxin neutralizing antibody response in children and adolescents infected or not with HIV.
    Vaccine. 2017 Jun 6. pii: S0264-410X(17)30748.
    >> Share

  42. GENITO CJ, Beck Z, Phares TW, Kalle F, et al
    Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Vaccine. 2017 Jun 5. pii: S0264-410X(17)30729.
    >> Share

    May 2017
  43. PAINTER JE, DiClemente RJ, Jimenez L, Stuart T, et al
    Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial.
    Vaccine. 2017 May 19. pii: S0264-410X(17)30632.
    >> Share

  44. BUCKINGHAM L, Becher J, Voytek CD, Fiore D, et al
    Going social: Success in online recruitment of men who have sex with men for prevention HIV vaccine research.
    Vaccine. 2017 May 16. pii: S0264-410X(17)30587.
    >> Share

  45. VIRNIK K, Nesti E, Dail C, Hockenbury M, et al
    Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30539.
    >> Share

  46. BOGGIANO C, Eichelberg K, Ramachandra L, Shea J, et al
    "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
    Vaccine. 2017 May 2. pii: S0264-410X(17)30467.
    >> Share

    April 2017
  47. HU D, Bowder D, Wei W, Thompson J, et al
    Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design.
    Vaccine. 2017 Apr 28. pii: S0264-410X(17)30546.
    >> Share

  48. SEREMBA E, Van Geertruyden JP, Ssenyonga R, Opio CK, et al
    Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.
    Vaccine. 2017 Apr 20. pii: S0264-410X(17)30484.
    >> Share

  49. MELNYCHUK L, Ajamian L, Jean-Pierre P, Liang J, et al
    Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.
    Vaccine. 2017 Apr 6. pii: S0264-410X(17)30355.
    >> Share

    March 2017
  50. TANG X, Guo J, Cheng L, Sun C, et al
    Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses.
    Vaccine. 2017 Mar 30. pii: S0264-410X(17)30389.
    >> Share

  51. SHI J, Feng Y, Gao L, Feng D, et al
    Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.
    Vaccine. 2017 Mar 23. pii: S0264-410X(17)30340.
    >> Share

  52. VAN REGENMORTEL MH
    Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV.
    Vaccine. 2017 Mar 17. pii: S0264-410X(17)30323.
    >> Share

  53. HUANG X, Zhu Q, Huang X, Yang L, et al
    In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Vaccine. 2017 Mar 16. pii: S0264-410X(17)30312.
    >> Share

  54. SEIB K, Pollard AJ, de Wals P, Andrews RM, et al
    Policy making for vaccine use as a driver of vaccine innovation and development in the developed world.
    Vaccine. 2017;35:1380-1389.
    >> Share

  55. SETH L, Bingham Ferlez KM, Kaba SA, Musser DM, et al
    Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
    Vaccine. 2017 Mar 5. pii: S0264-410X(17)30243.
    >> Share

  56. GIERSING BK, Vekemans J, Nava S, Kaslow DC, et al
    Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
    Vaccine. 2017 Mar 2. pii: S0264-410X(16)31205.
    >> Share

    February 2017
  57. LEVIN MJ, Huang S, Moscicki AB, Song LY, et al
    Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Vaccine. 2017 Feb 23. pii: S0264-410X(17)30215.
    >> Share

  58. BALASUBRAMANIAN P, Kumar R, Williams C, Itri V, et al
    Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.
    Vaccine. 2017 Feb 6. pii: S0264-410X(17)30089.
    >> Share

    January 2017
  59. HUANG Y, Zhang L, Janes H, Frahm N, et al
    Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.
    Vaccine. 2017 Jan 25. pii: S0264-410X(16)30879.
    >> Share

  60. ABARA WE, Collier MG, Teshale EH
    Impact of universal infant hepatitis B vaccination in the US-affiliated Pacific Islands, 1985-2015.
    Vaccine. 2017 Jan 20. pii: S0264-410X(17)30039.
    >> Share

  61. HOEST C, Seidman JC, Lee G, Platts-Mills JA, et al
    Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study.
    Vaccine. 2017;35:443-451.
    >> Share

  62. CHEGE GK, Burgers WA, Muller TL, Gray CM, et al
    DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
    Vaccine. 2017 Jan 6. pii: S0264-410X(16)31294.
    >> Share

  63. BREWER MG, DiPiazza A, Acklin J, Feng C, et al
    Nanoparticles decorated with viral antigens are more immunogenic at low surface density.
    Vaccine. 2017 Jan 3. pii: S0264-410X(16)31274.
    >> Share

    December 2016
  64. MATTHIESSEN L, Lang H, Klimathianaki M, Hanrahan F, et al
    European strategy for vaccine development against infectious diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)30952.
    >> Share

  65. POWELL AM, Luo Z, Martin L, Wan Z, et al
    The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)31233.
    >> Share

  66. RUAN S, Cai Y, Ramsay AJ, Welsh DA, et al
    B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31144.
    >> Share

  67. MOSERI A, Sinha E, Zommer H, Arshava B, et al
    Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization.
    Vaccine. 2016 Dec 7. pii: S0264-410X(16)31178.
    >> Share

    November 2016
  68. POTEET E, Lewis P, Chen C, Ho SO, et al
    Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
    Vaccine. 2016;34:5886-5894.
    >> Share

  69. ALLEMAN MM, Wannemuehler KA, Hao L, Perelygina L, et al
    Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy.
    Vaccine. 2016 Nov 17. pii: S0264-410X(16)30994.
    >> Share

  70. PEREIRA-MANFRO WF, Alvino RM, Cruz AC, Silva GP, et al
    Association of serum bactericidal antibody and opsonic antibody levels after Neisseria meningitidis serogroup C conjugate vaccine in Brazilian children and adolescents infected or not infected with HIV.
    Vaccine. 2016 Nov 12. pii: S0264-410X(16)31042.
    >> Share

  71. YU HT, Wang JY, Tian D, Wang MX, et al
    Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice.
    Vaccine. 2016 Nov 11. pii: S0264-410X(16)30998.
    >> Share

  72. FONTENOT HB, Fantasia HC, Vetters R, Zimet GD, et al
    Increasing HPV vaccination and eliminating barriers: Recommendations from young men who have sex with men.
    Vaccine. 2016 Nov 9. pii: S0264-410X(16)31026.
    >> Share

    October 2016
  73. HERTZ T, Logan MG, Rolland M, Magaret CA, et al
    A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Vaccine. 2016 Oct 15. pii: S0264-410X(16)30880.
    >> Share

  74. BAMFORD A, Manno EC, Mellado MJ, Spoulou V, et al
    Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation.
    Vaccine. 2016 Oct 7. pii: S0264-410X(16)30848.
    >> Share

  75. ABADOM TR, Smith AD, Tempia S, Madhi SA, et al
    Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-population study.
    Vaccine. 2016 Oct 6. pii: S0264-410X(16)30824.
    >> Share

    September 2016
  76. GIRARD MP, Le-Grand R, Picot V, Longuet C, et al
    Report of the Cent Gardes HIV Vaccines Conference, Part 2: The cellular immune response. Fondation Merieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.
    Vaccine. 2016 Sep 27. pii: S0264-410X(16)30847.
    >> Share

  77. HOLECHEK SA, McAfee MS, Nieves LM, Guzman VP, et al
    Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.
    Vaccine. 2016 Sep 23. pii: S0264-410X(16)30826.
    >> Share

  78. DZANIBE S, Adrian PV, Kimaro Mlacha SZ, Madhi SA, et al
    Natural acquired group B Streptococcus capsular polysaccharide and surface protein antibodies in HIV-infected and HIV-uninfected children.
    Vaccine. 2016 Sep 20. pii: S0264-410X(16)30828.
    >> Share

  79. MUNIER CM, van Bockel D, Bailey M, Ip S, et al
    The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype.
    Vaccine. 2016 Sep 14. pii: S0264-410X(16)30805.
    >> Share

  80. ANDERSSON AC, Ragonnaud E, Seaton KE, Sawant S, et al
    Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Vaccine. 2016 Sep 12. pii: S0264-410X(16)30798.
    >> Share

    August 2016
  81. CRUM-CIANFLONE NF, Won S, Lee R, Lalani T, et al
    Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults.
    Vaccine. 2016 Aug 28. pii: S0264-410X(16)30432.
    >> Share

  82. PENALOZA-MACMASTER P, Alayo QA, Ra J, Provine NM, et al
    Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.
    Vaccine. 2016 Aug 24. pii: S0264-410X(16)30733.
    >> Share

  83. MORO PL, Chen RT
    Obstetrical and neonatal case definitions for immunization safety data.
    Vaccine. 2016 Aug 20. pii: S0264-410X(16)30698.
    >> Share

  84. SUMNER RP, Ren H, Ferguson BJ, Smith GL, et al
    Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.
    Vaccine. 2016 Aug 17. pii: S0264-410X(16)30659.
    >> Share

  85. MONEY DM, Moses E, Blitz S, Vandriel SM, et al
    HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
    Vaccine. 2016 Aug 17. pii: S0264-410X(16)30673.
    >> Share

  86. WESTMAN ME, Malik R, Hall E, Harris M, et al
    The protective rate of the feline immunodeficiency virus vaccine: An Australian field study.
    Vaccine. 2016 Aug 10. pii: S0264-410X(16)30511.
    >> Share

  87. LI X, Huang J, Zhang M, Funakoshi R, et al
    Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice.
    Vaccine. 2016 Aug 5. pii: S0264-410X(16)30663.
    >> Share

    July 2016
  88. HERATH S, Le Heron A, Colloca S, Patterson S, et al
    Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors.
    Vaccine. 2016 Jul 21. pii: S0264-410X(16)30611.
    >> Share

  89. CLARKE DK, Hendry RM, Singh V, Rose JK, et al
    Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2016 Jul 6. pii: S0264-410X(16)30548.
    >> Share

  90. RITZ N, Casalaz D, Donath S, Tebruegge M, et al
    Comparable CD4 and CD8 T cell responses and cytokine release after at-birth and delayed BCG immunisation in infants born in Australia.
    Vaccine. 2016 Jul 5. pii: S0264-410X(16)30557.
    >> Share

    June 2016
  91. CONDIT RC, Williamson AL, Sheets R, Seligman SJ, et al
    Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.
    Vaccine. 2016 Jun 23. pii: S0264-410X(16)30225.
    >> Share

  92. WIYSONGE CS, Waggie Z, Hawkridge A, Schoub BD, et al
    The Cape Town Declaration on Vaccines 2012: Unlocking the full potential of vaccines in Africa.
    Vaccine. 2016 Jun 14. pii: S0264-410X(16)30398.
    >> Share

  93. ABDULLAHI LH, Kagina BM, Cassidy T, Adebayo EF, et al
    Knowledge, attitudes and practices on adolescent vaccination among adolescents, parents and teachers in Africa: A systematic review.
    Vaccine. 2016 Jun 8. pii: S0264-410X(16)30437.
    >> Share

    May 2016
  94. GIRARD MP, Le-Grand R, Picot V, Longuet C, et al
    Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Merieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.
    Vaccine. 2016 May 20. pii: S0264-410X(16)30314.
    >> Share

  95. THORNE A, Chowdhury F, Singer J, Keynan Y, et al
    Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults.
    Vaccine. 2016 May 19. pii: S0264-410X(16)30310.
    >> Share

  96. ZHANG Q, Liu Z, Hou J, Wang S, et al
    Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system.
    Vaccine. 2016 May 16. pii: S0264-410X(16)30295.
    >> Share

  97. ASTURIAS EJ, Wharton M, Pless R, MacDonald NE, et al
    Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.
    Vaccine. 2016 May 16. pii: S0264-410X(16)30301.
    >> Share

  98. VENEREO-SANCHEZ A, Gilbert R, Simoneau M, Caron A, et al
    Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Vaccine. 2016 May 4. pii: S0264-410X(16)30264.
    >> Share

  99. ALDHAMEN YA, Rastall DP, Chen W, Seregin SS, et al
    CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets.
    Vaccine. 2016 May 3. pii: S0264-410X(16)30233.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016